scholarly journals Field Comparison between Blood Immunochromatographic Card Test and Microscopy in Diagnosis of Bancroftian Filariasis in Northern Taraba State, Nigeria

2020 ◽  
Vol 3 (2) ◽  
Author(s):  
OS Elkanah ◽  
DS Elkanah ◽  
JA Wahedi ◽  
SL Kela ◽  
AB Samaila ◽  
...  
Keyword(s):  
Bancroftian Filariasis ◽  
Card Test

scholarly journals Current Epidemiological Assessment of Bancroftian Filariasis in Tanga Region, Northeastern Tanzania

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Happyness J. Mshana ◽  
Vito Baraka ◽  
Gerald Misinzo ◽  
Williams H. Makunde
Keyword(s):  
Lymphatic Filariasis ◽  
Current Status ◽  
Limited Information ◽  
Bancroftian Filariasis ◽  
Filarial Infection ◽  
Cross Sectional ◽  
Epidemiological Trend ◽  
Filarial Antigen ◽  
Elimination Programme ◽  
Card Test

Background. Tanzania started a countrywide lymphatic filariasis elimination programme in 2000 adopting the mass drug administration (MDA) strategy. The drug used for the programme was the combination of ivermectin and albendazole. However, there is limited information on the current epidemiological trend of the infections, where MDA implementation is ongoing. The present study aimed at assessing the current status of Bancroftian filariasis infection rate and morbidity where MDA has been distributed and administered for over eight rounds. Methodology. The study was a cross-sectional descriptive study involving 272 individuals (>18 years) from endemic communities in Tanga region where MDA has been implemented. Clinical, sociodemographic, and circulating filarial antigen (CFA) test was undertaken using immune chromatographic card test according to the manufacturer’s instructions. Results. A total of 472 individuals were screened: 307/472 (65.1%) were males while 165/472 (34.9%) were females. The overall prevalence of CFA was 5.51%, that of hydrocoele was 73.2%, and that of lymphoedema was 16.0%. The prevalence of hydrocoele combined with lymphoedema was 5.5%. Conclusion. Our findings demonstrate a considerable reduction in filarial infection. However, there is clear evidence of ongoing transmission despite the 8 rounds of MDA. It is unlikely that the annual MDA would interrupt filarial transmission; therefore, additional strategies are needed to accelerate lymphatic filariasis control and elimination.

Unusual case of bancroftian filariasis co-existing with chronic myeloid leukemia

2014 ◽  
Vol 7 (1) ◽  
pp. 64
Author(s):  
PreetiRihal Chakrabarti ◽  
Mallika Kinger ◽  
Priyanka Kiyawat ◽  
Surabhi Sharma
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Unusual Case ◽  
Bancroftian Filariasis

scholarly journals Acute eosinophilic glomerulonephritis with Bancroftian filariasis

1979 ◽  
Vol 55 (650) ◽  
pp. 905-907 ◽  
Author(s):  
A. Date ◽  
V. Gunasekaran ◽  
M. G. Kirubakaran ◽  
J. C. M. Shastry
Keyword(s):  
Bancroftian Filariasis

Semiannual Treatment of Albendazole Alone is Efficacious for Treatment of Lymphatic Filariasis: A Randomized Open-label Trial in Cote d'Ivoire

2021 ◽  
Author(s):  
Allassane F Ouattara ◽  
Catherine M Bjerum ◽  
Méité Aboulaye ◽  
Olivier Kouadio ◽  
Vanga K Marius ◽  
...  
Keyword(s):  
Lymphatic Filariasis ◽  
Primary Outcome ◽  
Central Africa ◽  
Wuchereria Bancrofti ◽  
Bancroftian Filariasis ◽  
Loa Loa ◽  
Open Label ◽  
Treatment Groups ◽  
Open Label Trial ◽  
To Receive

Abstract Background Ivermectin (IVM) plus albendazole (ALB), or IA, is widely used in mass drug administration (MDA) programs that aim to eliminate lymphatic filariasis (LF) in Africa. However, IVM can cause severe adverse events in persons with heavy Loa loa infections that are common in Central Africa. ALB is safe in loiasis, but more information is needed on its efficacy for LF. This study compared the efficacy and safety of three years of semiannual treatment with ALB to annual IA in persons with bancroftian filariasis. Methods Adults with Wuchereria bancrofti microfilaremia (Mf) were randomized to receive either three annual doses of IA (N=52), six semiannual doses of ALB 400mg (N=45), or six semiannual doses of ALB 800mg (N=47). The primary outcome amicrofilaremia at 36 months. Findings IA was more effective for completely clearing Mf than ALB 400mg or ALB 800mg (79%, CI 67-91; vs. 48%, CI 32-66 and 57%, CI 41-73, respectively). Mean % reductions in Mf counts at 36 months relative to baseline tended to be greater after IA (98%, CI 88-100) than after ALB 400mg (88%, CI 78-98) and ALB 800mg (89%, CI 79-99) (P=0.07 and P=0.06, respectively). Adult worm nest numbers (assessed by ultrasound) were reduced in all treatment groups. Treatments were well tolerated. Interpretation Repeated semiannual treatment with ALB is macrofilaricidal for W. bancrofti and leads to sustained reductions in Mf counts. This is a safe and effective regimen that could be used as MDA to eliminate LF in areas ivermectin cannot be used.

Bancroftian filariasis in two urban areas of Recife, Brazil: pre-control observations on infection and disease

1995 ◽  
Vol 89 (4) ◽  
pp. 373-377 ◽  
Author(s):  
M.F.M. Albuquerque ◽  
M.C. Marzochi ◽  
P.C. Sabroza ◽  
M.C. Braga ◽  
T. Padilha ◽  
...  
Keyword(s):  
Urban Areas ◽  
Bancroftian Filariasis
Sign in / Sign up

Export Citation Format

Share Document